ストックスクリーナーアプリを入手
9.34
1.16%
-0.11
アフターアワーズ：
9.34
前日終値:
$9.45
開ける：
$9.02
24時間の取引高:
1.22M
Relative Volume:
0.94
時価総額：
$638.64M
収益：
-
当期純損益:
$-297.11M
株価収益率:
-2.1324
EPS:
-4.38
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
+6.38%
1か月 パフォーマンス:
-43.70%
6か月 パフォーマンス:
-9.76%
1年 パフォーマンス:
+33.62%
1日の値動き範囲:
$8.95
$9.98
1週間の範囲:
$8.495
$9.98
52週間の値動き範囲:
$6.065
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| PHAT | 9.34 | 638.64M | 0 | -297.11M | -216.95M | -4.38 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownHere's Why - MarketBeat
Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Phathom Pharmaceuticals - The Healthcare Technology Report.
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register
Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Phathom Pharmaceuticals Reports Significant Revenue Growth - TipRanks
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Previ - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
Jennison Associates LLC's Strategic Acquisition in Phathom Pharm - GuruFocus.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% - Yahoo Finance
Phathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action InvestigationPHAT - Marketscreener.com
Phathom Pharmaceuticals to Report Third Quarter 2024 - GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business - The Bakersfield Californian
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the - GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - Yahoo Finance
Where are the Opportunities in (PHAT) - Stock Traders Daily
Some of the Gastroesophageal Reflux Disease Therapeutics market players are: - InsightAce Analytic
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Creative Planning Has $278,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 6.8%Time to Buy? - MarketBeat
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2024. - Marketscreener.com
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
A year in review: Phathom Pharmaceuticals Inc (PHAT)’s performance in the last year - US Post News
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.4%Time to Sell? - MarketBeat
PHAT’s 52-Week Rollercoaster: From $6.07 to $19.71 – What’s Next for Investors? - The InvestChronicle
Financial Health Report: Phathom Pharmaceuticals Inc (PHAT)’s Ratios Tell a Tale - The Dwinnex
Learn to Evaluate (PHAT) using the Charts - Stock Traders Daily
A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News
PHAT Stock Sees Decline of Approximately -13.44% in Last Five Days - Knox Daily
PHAT Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
PHAT (Phathom Pharmaceuticals Inc) may reap gains as insiders became active recently - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.5%Here's What Happened - MarketBeat
Daily Market Movement: Phathom Pharmaceuticals Inc (PHAT) Sees a -4.96 Decrease, Closing at 17.25 - The Dwinnex
A new trading data show Phathom Pharmaceuticals Inc (PHAT) is showing positive returns. - SETE News
Marshall Wace LLP Invests $1.16 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals Inc Inc. (PHAT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.8%Here's Why - MarketBeat
The Potential Rise in the Price of Phathom Pharmaceuticals Inc (PHAT) following insiders activity - Knox Daily
Have you been able to find a good deal on Phathom Pharmaceuticals Inc’s shares? - US Post News
Phathom Pharmaceuticals Inc (PHAT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
Phathom Pharmaceuticals Inc (PHAT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Henderson Molly | CFO and CBO |
Jul 15 '24 |
Sale |
11.72 |
4,325 |
50,689 |
99,447 |
| Curran Terrie | President and Chief Executive |
Jul 15 '24 |
Sale |
11.72 |
33,848 |
396,699 |
377,734 |
| Henderson Molly | CFO and CBO |
Apr 08 '24 |
Sale |
11.10 |
3,435 |
38,128 |
95,263 |
| Curran Terrie | President and Chief Executive |
Mar 22 '24 |
Sale |
9.11 |
16,851 |
153,513 |
410,784 |
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner |
Jan 24 '24 |
Sale |
8.10 |
3,703,703 |
29,999,994 |
3,755,583 |
| Henderson Molly | CFO and CBO |
Jan 19 '24 |
Sale |
7.75 |
6,307 |
48,900 |
98,698 |
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):